Trial Profile
Quality of Life in Greek Hemodialysis Patients Receiving Zemplar i.v (QualitiZe)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Paricalcitol (Primary)
- Indications Secondary hyperparathyroidism
- Focus Therapeutic Use
- Acronyms QUALITIZE
- Sponsors Abbott Laboratories; AbbVie
- 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 22 Oct 2012 Planned End Date changed from 1 Nov 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.